The metabolic battleground must now shift from peak weight loss to flexible maintenance protocols.
As early trial data plateaus, metabolic drug developers are shifting clinical trials toward flexible, low-dose, and transitional maintenance regimens to manage costs and patient adherence.
The same conclusion keeps arriving from across the workspace's research — 2 topics independently instantiate this theme. Filter the evidence by where it came from:
Viking Therapeutics is proactively evaluating transitions to monthly subcutaneous or oral dosing to establish flexible weight-maintenance protocols.
A market leader is launching trials to validate lower maintenance strengths specifically to address patient-driven real-world dosing habits.
This trial illustrates the clinical push to prove oral drugs can successfully maintain weight loss after patients stop weekly injectables.
Viking is actively testing less frequent maintenance dosing intervals to sustain weight loss and improve patient adherence.